{
    "hands_on_practices": [
        {
            "introduction": "A core tenet of medical ethics, non-maleficence, demands that we first do no harm. In the context of a powerful, irreversible technology like germline editing, this principle is often invoked through the lens of precaution. This exercise  challenges you to move beyond qualitative discussion and operationalize this precautionary stance by constructing a quantitative, data-driven rule for safety. You will use a Bayesian statistical framework to determine the minimum amount of preclinical evidence needed to be sufficiently confident that the risk of off-target effects is acceptably low before proceeding with first-in-human trials.",
            "id": "4337748",
            "problem": "A research consortium planning first-in-human germline genome editing seeks to set a preclinical evidence threshold grounded in Bayesian decision-making to honor the biomedical ethics principles of nonmaleficence and the precautionary principle. Define the probability of a severe off-target genomic alteration per standardized edit as $p \\in [0,1]$. Ethical safety for first-in-human trials is operationalized as $p \\leq \\theta$, with $\\theta = 0.01$. Prior to any human use, the consortium mandates that the Bayesian posterior probability of safety, $\\Pr(p \\leq \\theta \\mid \\text{data})$, must exceed $0.95$.\n\nAssume preclinical edits are conducted in a validated high-fidelity in vitro model and that:\n- Each edit is an independent Bernoulli trial with probability $p$ of a severe off-target event that would be clinically significant if it occurred in humans.\n- Severe off-target events are detected without error under the protocol.\n- The prior on $p$ is $\\text{Beta}(\\alpha_{0}, \\beta_{0})$ with $\\alpha_{0} = 1$ and $\\beta_{0} = 1$ to reflect prior ignorance over $[0,1]$.\n\nLet $n$ denote the number of independent preclinical edits conducted and $k$ the number of observed severe off-target events. Under the ethical policy, progression to first-in-human trials requires that $\\Pr(p \\leq \\theta \\mid k, n) > 0.95$. Suppose the preclinical program proceeds until no severe off-target events have been observed, i.e., $k = 0$. Derive, from first principles, the minimal integer $n$ such that the policy criterion is satisfied for $\\theta = 0.01$ and report that minimal $n$ as a single number. No rounding is required beyond choosing the minimal integer that achieves the criterion. The answer is unitless.",
            "solution": "The problem requires the determination of the minimum number of independent preclinical edits, $n$, that must be conducted without any observed severe off-target events ($k=0$) to satisfy a specific ethical safety criterion. This criterion is formulated within a Bayesian statistical framework.\n\n### Step 1: Problem Formulation and Model Specification\nThe problem defines the unknown probability of a severe off-target event as $p$. The data-generating process is a series of $n$ independent Bernoulli trials, where each trial results in an off-target event with probability $p$. The number of observed events, $k$, in $n$ trials follows a Binomial distribution, with the likelihood function given by:\n$$ L(p \\mid k, n) = \\binom{n}{k} p^k (1-p)^{n-k} $$\nThe prior belief about the parameter $p$ is modeled by a Beta distribution, $p \\sim \\text{Beta}(\\alpha_0, \\beta_0)$. The probability density function (PDF) of the prior is:\n$$ f(p; \\alpha_0, \\beta_0) = \\frac{p^{\\alpha_0-1}(1-p)^{\\beta_0-1}}{B(\\alpha_0, \\beta_0)} $$\nwhere $B(\\alpha_0, \\beta_0)$ is the Beta function. We are given the prior parameters $\\alpha_0=1$ and $\\beta_0=1$, which corresponds to a uniform distribution on the interval $[0,1]$, expressing maximal prior uncertainty about $p$.\n\n### Step 2: Derivation of the Posterior Distribution\nThe Beta distribution is a conjugate prior for the Bernoulli/Binomial likelihood. This means that the posterior distribution of $p$, given the data $(k, n)$, is also a Beta distribution. The posterior PDF is proportional to the product of the prior PDF and the likelihood function:\n$$ f(p \\mid k, n) \\propto L(p \\mid k, n) \\times f(p; \\alpha_0, \\beta_0) $$\n$$ f(p \\mid k, n) \\propto p^k (1-p)^{n-k} \\times p^{\\alpha_0-1}(1-p)^{\\beta_0-1} $$\n$$ f(p \\mid k, n) \\propto p^{\\alpha_0+k-1} (1-p)^{\\beta_0+n-k-1} $$\nThis is the kernel of a Beta distribution with updated parameters $\\alpha_{\\text{post}} = \\alpha_0 + k$ and $\\beta_{\\text{post}} = \\beta_0 + n - k$. Thus, the posterior distribution is:\n$$ p \\mid k,n \\sim \\text{Beta}(\\alpha_0 + k, \\beta_0 + n - k) $$\nThe problem specifies that no severe off-target events are observed, so $k=0$. Substituting the given values $\\alpha_0=1$, $\\beta_0=1$, and $k=0$, the posterior parameters become:\n$$ \\alpha_{\\text{post}} = 1 + 0 = 1 $$\n$$ \\beta_{\\text{post}} = 1 + n - 0 = n + 1 $$\nTherefore, the posterior distribution of $p$ is $p \\mid k=0, n \\sim \\text{Beta}(1, n+1)$.\n\n### Step 3: Application of the Ethical Policy Criterion\nThe ethical policy requires that the posterior probability of safety, defined as $p \\leq \\theta$, must be greater than $0.95$. The safety threshold is given as $\\theta = 0.01$. Mathematically, this condition is:\n$$ \\Pr(p \\leq \\theta \\mid k=0, n) > 0.95 $$\nThis probability is the cumulative distribution function (CDF) of the posterior distribution, $\\text{Beta}(1, n+1)$, evaluated at $p=\\theta$. The CDF of a Beta distribution $\\text{Beta}(\\alpha, \\beta)$ is given by the integral:\n$$ F(x; \\alpha, \\beta) = \\int_0^x \\frac{t^{\\alpha-1}(1-t)^{\\beta-1}}{B(\\alpha, \\beta)} dt $$\nFor our posterior distribution $\\text{Beta}(1, n+1)$ and threshold $\\theta=0.01$, this becomes:\n$$ \\Pr(p \\leq 0.01 \\mid k=0, n) = \\int_0^{0.01} \\frac{t^{1-1}(1-t)^{(n+1)-1}}{B(1, n+1)} dt = \\frac{1}{B(1, n+1)} \\int_0^{0.01} (1-t)^n dt $$\nFirst, we evaluate the Beta function $B(1, n+1) = \\frac{\\Gamma(1)\\Gamma(n+1)}{\\Gamma(1+n+1)} = \\frac{0! \\cdot n!}{(n+1)!} = \\frac{1}{n+1}$, where $\\Gamma$ is the Gamma function.\nNext, we evaluate the integral:\n$$ \\int_0^{0.01} (1-t)^n dt = \\left[ -\\frac{(1-t)^{n+1}}{n+1} \\right]_0^{0.01} = \\left(-\\frac{(1-0.01)^{n+1}}{n+1}\\right) - \\left(-\\frac{(1-0)^{n+1}}{n+1}\\right) = \\frac{1 - (0.99)^{n+1}}{n+1} $$\nCombining these results, the posterior probability is:\n$$ \\Pr(p \\leq 0.01 \\mid k=0, n) = (n+1) \\times \\left( \\frac{1 - (0.99)^{n+1}}{n+1} \\right) = 1 - (0.99)^{n+1} $$\n\n### Step 4: Solving for the Minimal Number of Edits, n\nWe must find the minimal integer $n$ that satisfies the inequality derived from the policy criterion:\n$$ 1 - (0.99)^{n+1} > 0.95 $$\nRearranging the inequality:\n$$ 0.05 > (0.99)^{n+1} $$\nTo solve for $n$, we take the natural logarithm of both sides. Since the natural logarithm is a strictly increasing function, the direction of the inequality is preserved.\n$$ \\ln(0.05) > \\ln\\left((0.99)^{n+1}\\right) $$\n$$ \\ln(0.05) > (n+1) \\ln(0.99) $$\nThe value of $\\ln(0.99)$ is negative because its argument is less than $1$. Therefore, dividing by $\\ln(0.99)$ reverses the direction of the inequality:\n$$ \\frac{\\ln(0.05)}{\\ln(0.99)} < n+1 $$\nSolving for $n$:\n$$ n > \\frac{\\ln(0.05)}{\\ln(0.99)} - 1 $$\nNow, we compute the numerical value of the right-hand side:\n$$ \\frac{\\ln(0.05)}{\\ln(0.99)} \\approx \\frac{-2.99573}{-0.01005} \\approx 298.08 $$\nSo the inequality becomes:\n$$ n > 298.08 - 1 $$\n$$ n > 297.08 $$\nSince $n$ must be an integer representing the number of edits, the minimal integer $n$ that satisfies this condition is $298$.\nThis means that a minimum of $298$ preclinical edits must be performed with zero observed severe off-target events to meet the consortium's ethical standard for proceeding to first-in-human trials.",
            "answer": "$$\\boxed{298}$$"
        },
        {
            "introduction": "The ethical debate surrounding germline editing extends beyond the future person to the very process of creating them. Because current protocols are imperfect and rely on screening, they inevitably involve the creation and subsequent discard of embryos that do not meet quality criteria, a point of significant ethical contention. This practice  guides you through the use of fundamental probability theory to model this process, allowing you to calculate the expected number of discarded embryos—a direct, quantifiable 'cost' of the procedure—and evaluate it against a formal ethical-proportionality test.",
            "id": "4337785",
            "problem": "A research consortium is evaluating a human germline genome editing protocol intended to prevent transmission of a severe monogenic disorder. Embryos are edited ex vivo and are subjected to rigorous genomic quality control. An embryo is considered suitable for transfer if it meets both on-target correction and off-target safety criteria. Assume the following scientifically and ethically grounded modeling assumptions:\n\n- Each edited embryo independently has probability $p$ of meeting the suitability criteria. If an embryo fails to meet the criteria, it is discarded and a new embryo is edited. This process continues until the first suitable embryo is obtained for transfer.\n- Let $T$ denote the total number of embryos edited until the first suitable embryo is obtained; $T$ takes values in $\\{1,2,3,\\dots\\}$.\n- The expected number of discarded embryos equals the expected value of $T-1$.\n- To assess ethical proportionality, suppose each discarded embryo contributes a harm weight $h$ measured in normalized harm units, and the expected clinical and social benefit to the future person and family attributable to preventing the monogenic disorder is $B$ in the same normalized units. A proportionality test will deem the protocol ethically acceptable if the expected harm is less than or equal to a fraction $\\alpha$ of the expected benefit, that is, if $\\mathbb{E}[\\text{harm}] \\leq \\alpha B$.\n\nUse only foundational definitions of Bernoulli trials, geometric stopping times, and the definition of expected value to derive the expected number of discarded embryos as a function of $p$, without invoking any pre-stated shortcut formulas. Then evaluate it for $p=0.2$. Next, using the proportionality rule with $h=1$, $B=10$, and $\\alpha=0.6$, determine whether the expected harm satisfies the proportionality condition, and briefly justify your determination in words.\n\nProvide as your final numeric answer the expected number of discarded embryos for $p=0.2$. No rounding is required.",
            "solution": "### Solution Derivation\nThe process described is a sequence of independent Bernoulli trials, where the probability of \"success\" (a suitable embryo) is $p$. The random variable $T$ represents the number of trials required to achieve the first success. This is, by definition, a geometrically distributed random variable.\n\nThe probability mass function (PMF) for $T$ is given by the probability of having $k-1$ failures followed by one success. The probability of failure for a single trial is $1-p$. Thus, the PMF is:\n$$P(T=k) = (1-p)^{k-1}p, \\quad \\text{for } k=1, 2, 3, \\dots$$\n\nThe problem requires the derivation of the expected number of discarded embryos, which is $\\mathbb{E}[T-1]$, from first principles. By the linearity of the expectation operator, we have:\n$$\\mathbb{E}[T-1] = \\mathbb{E}[T] - 1$$\n\nWe must first derive the expected value of $T$, $\\mathbb{E}[T]$. By the definition of expected value for a discrete random variable:\n$$\\mathbb{E}[T] = \\sum_{k=1}^{\\infty} k \\cdot P(T=k) = \\sum_{k=1}^{\\infty} k (1-p)^{k-1}p$$\n\nTo simplify the notation, let $q = 1-p$. The expression for the expectation becomes:\n$$\\mathbb{E}[T] = p \\sum_{k=1}^{\\infty} k q^{k-1}$$\nThe summation term is an arithmetic-geometric series. We can evaluate it by recognizing its relationship to the geometric series. Consider the standard geometric series formula for $|q|<1$:\n$$\\sum_{k=0}^{\\infty} q^k = 1 + q + q^2 + q^3 + \\dots = \\frac{1}{1-q}$$\nSince $p$ is a probability, $0 < p \\leq 1$, which implies $0 \\leq q < 1$. Thus, the condition for convergence is met.\n\nDifferentiating both sides of the geometric series formula with respect to $q$:\n$$\\frac{d}{dq} \\left( \\sum_{k=0}^{\\infty} q^k \\right) = \\frac{d}{dq} \\left( \\frac{1}{1-q} \\right)$$\nThe derivative of the sum, by term-by-term differentiation, is:\n$$\\frac{d}{dq} \\left( \\sum_{k=0}^{\\infty} q^k \\right) = \\sum_{k=1}^{\\infty} k q^{k-1} = 1 + 2q + 3q^2 + \\dots$$\nThe derivative of the right-hand side is:\n$$\\frac{d}{dq} \\left( (1-q)^{-1} \\right) = -1 \\cdot (1-q)^{-2} \\cdot (-1) = \\frac{1}{(1-q)^2}$$\nEquating the two results gives:\n$$\\sum_{k=1}^{\\infty} k q^{k-1} = \\frac{1}{(1-q)^2}$$\nNow, we substitute this back into our expression for $\\mathbb{E}[T]$:\n$$\\mathbb{E}[T] = p \\left( \\frac{1}{(1-q)^2} \\right)$$\nSubstituting $q = 1-p$ back into this equation:\n$$\\mathbb{E}[T] = p \\left( \\frac{1}{(1 - (1-p))^2} \\right) = p \\left( \\frac{1}{p^2} \\right) = \\frac{1}{p}$$\nHaving derived $\\mathbb{E}[T]$ from first principles, we can now find the expected number of discarded embryos:\n$$\\mathbb{E}[T-1] = \\mathbb{E}[T] - 1 = \\frac{1}{p} - 1 = \\frac{1-p}{p}$$\n\nNow, we evaluate this for the given value $p=0.2$:\n$$\\mathbb{E}[T-1] = \\frac{1-0.2}{0.2} = \\frac{0.8}{0.2} = 4$$\nThe expected number of discarded embryos is $4$. This is the final numeric answer requested.\n\nFinally, we apply the proportionality test. The total expected harm is the expected number of discarded embryos multiplied by the harm weight $h$:\n$$\\mathbb{E}[\\text{harm}] = h \\cdot \\mathbb{E}[T-1]$$\nUsing the given values $h=1$ and our calculated $\\mathbb{E}[T-1]=4$:\n$$\\mathbb{E}[\\text{harm}] = 1 \\times 4 = 4$$\nThe ethical threshold for harm is given by $\\alpha B$. Using the given values $\\alpha=0.6$ and $B=10$:\n$$\\alpha B = 0.6 \\times 10 = 6$$\nThe proportionality test requires that $\\mathbb{E}[\\text{harm}] \\leq \\alpha B$. We check this condition with our calculated values:\n$$4 \\leq 6$$\nThe inequality holds true.\n\nThe determination is that the protocol is ethically acceptable under the specified proportionality test. The justification is that the calculated expected harm of $4$ normalized units is less than the maximum acceptable harm threshold of $6$ normalized units as defined by the condition $\\alpha B$.",
            "answer": "$$\\boxed{4}$$"
        },
        {
            "introduction": "While editing single-gene disorders presents a clear therapeutic target, the ethical landscape becomes far more complex when considering common, polygenic diseases. In these cases, genetic contributions to risk are diffuse, and any intervention may offer only a modest statistical benefit. This problem  thrusts you into this complex scenario, where you must apply principles of genetic epidemiology to calculate the absolute risk reduction achieved by modifying a Polygenic Risk Score ($PRS$) and then weigh this marginal benefit against the intervention's inherent risks and its profound implications for justice and the therapy-enhancement distinction.",
            "id": "4337776",
            "problem": "A research program in precision medicine proposes to use human germline genome editing to reduce risk of a common adult-onset, polygenic disease by lowering an embryo’s Polygenic Risk Score (PRS). In a large, well-calibrated cohort, the disease’s baseline lifetime absolute risk at the population mean PRS is measured as $p_{0} = 0.10$. Genetic epidemiology establishes that, under a standard logit-risk model, the odds of disease scale multiplicatively with PRS, such that a change of $1$ standard deviation in PRS multiplies the odds by the odds ratio per standard deviation (OR), here $OR = 1.5$. A proposed edit is expected to decrease the embryo’s PRS by $\\Delta \\mathrm{PRS} = 1$ standard deviation relative to the population mean. Using only core definitions of odds and odds ratios, and the assumption that odds scale multiplicatively with PRS under the logit model, compute the absolute risk reduction $\\Delta p$ for the individual, defined as $\\Delta p = p_{0} - p_{1}$, where $p_{1}$ is the post-edit absolute risk. Express the final $\\Delta p$ as a decimal and round your answer to four significant figures.\n\nSeparately, briefly articulate whether undertaking such a germline edit is ethically acceptable under a precautionary expected-utility framing in which the probability of a serious off-target consequence is $q = 1.0 \\times 10^{-3}$ and the disutility of that consequence is taken to be equal to the disutility of experiencing the disease once over a lifetime. Your ethical discussion should rely on first principles from bioethics (for example, expected utility, nonmaleficence, autonomy, and justice), but your numerical final answer must be only the computed $\\Delta p$ rounded as specified.",
            "solution": "### Solution Derivation\n\n**Part 1: Calculation of Absolute Risk Reduction ($\\Delta p$)**\n\nThe solution requires translating between probability (risk) and odds. The odds of an event with probability $p$ are defined as the ratio of the probability of the event occurring to the probability of it not occurring.\n$$\nO = \\frac{p}{1-p}\n$$\nConversely, probability can be expressed in terms of odds:\n$$\np = \\frac{O}{1+O}\n$$\nFirst, we calculate the baseline odds, $O_{0}$, corresponding to the baseline risk, $p_{0}$, at the population mean PRS.\nGiven $p_{0} = 0.10$:\n$$\nO_{0} = \\frac{p_{0}}{1 - p_{0}} = \\frac{0.10}{1 - 0.10} = \\frac{0.10}{0.90} = \\frac{1}{9}\n$$\nThe problem states that the odds ratio per standard deviation is $OR = 1.5$. An odds ratio is the factor by which the odds are multiplied for a given change in an exposure variable. Here, the exposure variable is the PRS, and the change is measured in standard deviations. The model is multiplicative, meaning for a change of $\\Delta \\mathrm{PRS}$ standard deviations, the new odds $O_{1}$ are related to the old odds $O_{0}$ by:\n$$\nO_{1} = O_{0} \\times (OR)^{\\Delta \\mathrm{PRS}}\n$$\nThe proposed edit is expected to decrease the PRS by $1$ standard deviation, so $\\Delta \\mathrm{PRS} = -1$.\n$$\nO_{1} = O_{0} \\times (1.5)^{-1} = \\frac{O_{0}}{1.5}\n$$\nSubstituting the value of $O_{0}$:\n$$\nO_{1} = \\frac{1/9}{1.5} = \\frac{1/9}{3/2} = \\frac{1}{9} \\times \\frac{2}{3} = \\frac{2}{27}\n$$\nNext, we convert the post-edit odds, $O_{1}$, back to the post-edit absolute risk, $p_{1}$.\n$$\np_{1} = \\frac{O_{1}}{1 + O_{1}} = \\frac{2/27}{1 + 2/27} = \\frac{2/27}{29/27} = \\frac{2}{29}\n$$\nFinally, we compute the absolute risk reduction, $\\Delta p$, which is defined as $\\Delta p = p_{0} - p_{1}$.\n$$\n\\Delta p = \\frac{1}{10} - \\frac{2}{29} = \\frac{1 \\times 29 - 2 \\times 10}{10 \\times 29} = \\frac{29 - 20}{290} = \\frac{9}{290}\n$$\nTo provide the final answer as a decimal rounded to four significant figures, we perform the division:\n$$\n\\Delta p = \\frac{9}{290} \\approx 0.03103448...\n$$\nRounding to four significant figures gives:\n$$\n\\Delta p \\approx 0.03103\n$$\n\n**Part 2: Ethical Analysis**\n\nThe problem asks for a brief articulation on the ethical acceptability of the germline edit.\n\nUnder the specified \"precautionary expected-utility framing,\" we compare the expected utility of the two actions: performing the edit versus not performing it. Let $D$ be the disutility of experiencing the disease, where $D > 0$. The problem states the disutility of a serious off-target consequence is also $D$. We can set the utility of a healthy life to $0$.\n\nThe expected utility without the edit is determined by the baseline risk $p_{0}$:\n$$\nE[U_{\\text{no-edit}}] = p_{0} \\times (-D) + (1-p_{0}) \\times 0 = -p_{0}D = -0.10 D\n$$\nThe expected utility with the edit must account for both the reduced risk of disease, $p_{1}$, and the new risk of an off-target consequence, $q$. The total probability of a negative outcome is the sum of two mutually exclusive events: (A) no off-target effect occurs (probability $1-q$) but the person gets the disease anyway (probability $p_{1}$), and (B) an off-target effect occurs (probability $q$). The total risk of a negative outcome of disutility $D$ is $P(\\text{bad outcome}) = (1-q)p_{1} + q$.\n$$\nE[U_{\\text{edit}}] = - ((1-q)p_{1} + q)D\n$$\nUsing the values $p_{1} = 2/29$ and $q = 1.0 \\times 10^{-3} = 0.001$:\n$$\nE[U_{\\text{edit}}] = - \\left( \\left(1 - 0.001\\right) \\frac{2}{29} + 0.001 \\right) D = - \\left( 0.999 \\times \\frac{2}{29} + 0.001 \\right) D \\approx - (0.068897 + 0.001) D = -0.069897 D\n$$\nComparing the utilities, the edit is preferable if $E[U_{\\text{edit}}] > E[U_{\\text{no-edit}}]$, which means $-0.069897 D > -0.10 D$. Since $D > 0$, this simplifies to $0.069897 < 0.10$, which is true. Thus, within this narrow framing, the edit increases expected utility and appears ethically acceptable.\n\nHowever, a rigorous bioethical analysis must extend beyond this simplified calculation.\n1.  **Non-maleficence and the Precautionary Principle**: The term \"precautionary\" in the problem's framing is in tension with the pure utility calculation. The precautionary principle urges caution in the face of uncertain, potentially irreversible, and catastrophic harms. Human germline editing is such a case. The probability $q$ is an estimate, and the nature of \"serious off-target consequences\" is unknown and could be far worse than the disease in question. The assumption that the disutilities are equal is a critical and likely invalid simplification. The effects are heritable, affecting all subsequent generations without their consent, amplifying the potential for harm.\n2.  **Autonomy**: The prospective embryo, who is the subject of the intervention, cannot provide consent. This lack of consent from the person whose genome is being altered is a fundamental ethical barrier. While parents have proxy decision-making authority, it is traditionally limited to established treatments, not permanent, heritable alterations with unknown long-term consequences.\n3.  **Justice**: If this technology is expensive, its availability will likely be limited to the affluent. This would create a societal divide between the 'genetically enhanced' and the unenhanced, exacerbating existing health and social inequalities. It raises questions about resource allocation: the modest absolute risk reduction of $\\approx 3.1\\%$ for an individual may not justify the societal cost and risk, especially when compared to public health measures that benefit the whole population.\n\nIn conclusion, while a simplistic expected-utility calculation based on the given parameters suggests a net benefit, it is an insufficient basis for ethical approval. The profound implications for future generations, the violation of individual autonomy, and the high potential for social injustice are grave concerns that lead many bioethicists to argue that such an intervention is not ethically acceptable at the present time, regardless of a narrowly positive utility calculation.",
            "answer": "$$\\boxed{0.03103}$$"
        }
    ]
}